JP2021515749A5 - - Google Patents
Info
- Publication number
- JP2021515749A5 JP2021515749A5 JP2020544266A JP2020544266A JP2021515749A5 JP 2021515749 A5 JP2021515749 A5 JP 2021515749A5 JP 2020544266 A JP2020544266 A JP 2020544266A JP 2020544266 A JP2020544266 A JP 2020544266A JP 2021515749 A5 JP2021515749 A5 JP 2021515749A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutically acceptable
- acceptable salt
- treatment
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1803340.7 | 2018-03-01 | ||
| GBGB1803340.7A GB201803340D0 (en) | 2018-03-01 | 2018-03-01 | Compounds |
| PCT/GB2019/050578 WO2019166822A1 (en) | 2018-03-01 | 2019-03-01 | Compounds that modulates ampa receptor function |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515749A JP2021515749A (ja) | 2021-06-24 |
| JP2021515749A5 true JP2021515749A5 (enExample) | 2022-02-25 |
| JP7225255B2 JP7225255B2 (ja) | 2023-02-20 |
Family
ID=61903711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544266A Active JP7225255B2 (ja) | 2018-03-01 | 2019-03-01 | Ａｍｐａ受容体機能を調節する化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11298345B2 (enExample) |
| EP (1) | EP3759092B1 (enExample) |
| JP (1) | JP7225255B2 (enExample) |
| KR (2) | KR20250093578A (enExample) |
| CN (1) | CN112004811B (enExample) |
| AU (1) | AU2019226718C1 (enExample) |
| BR (1) | BR112020017739A2 (enExample) |
| CA (1) | CA3091783A1 (enExample) |
| DK (1) | DK3759092T3 (enExample) |
| ES (1) | ES2970784T3 (enExample) |
| FI (1) | FI3759092T3 (enExample) |
| GB (1) | GB201803340D0 (enExample) |
| MX (1) | MX2020009097A (enExample) |
| PL (1) | PL3759092T3 (enExample) |
| RU (1) | RU2020127537A (enExample) |
| WO (1) | WO2019166822A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| WO2001096308A1 (en) | 2000-06-12 | 2001-12-20 | Eisai Co., Ltd. | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| RU2279428C2 (ru) | 2000-09-18 | 2006-07-10 | Эйсай Ко., Лтд. | Производные пиридазинона и триазинона и их применение в качестве фармацевтических препаратов |
| AU2003302027A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| WO2006109056A1 (en) | 2005-04-12 | 2006-10-19 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| TW200812975A (en) | 2006-03-20 | 2008-03-16 | Glaxo Group Ltd | Compounds which potentiate AMPA receptor and uses thereof in medicine |
| ATE543798T1 (de) | 2006-04-24 | 2012-02-15 | Lilly Co Eli | Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1 |
| TW200817385A (en) | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
| EP2086643B1 (en) | 2006-11-03 | 2011-03-23 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| GB0711088D0 (en) * | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| GB0711089D0 (en) | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| JP5451611B2 (ja) | 2007-07-26 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター |
| NZ584098A (en) | 2007-09-20 | 2012-05-25 | Cortex Pharma Inc | 3-substituted 1,2,3-triazin-4-one's and 3-substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses |
| GB0721094D0 (en) | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| TW201004945A (en) | 2008-05-01 | 2010-02-01 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| TW201012803A (en) | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| TW201031649A (en) * | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
| AU2010264095B2 (en) | 2009-06-26 | 2013-07-11 | Biogen Ma Inc. | Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof |
| WO2011132051A2 (en) * | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
-
2018
- 2018-03-01 GB GBGB1803340.7A patent/GB201803340D0/en not_active Ceased
-
2019
- 2019-03-01 KR KR1020257019599A patent/KR20250093578A/ko active Pending
- 2019-03-01 EP EP19710107.4A patent/EP3759092B1/en active Active
- 2019-03-01 DK DK19710107.4T patent/DK3759092T3/da active
- 2019-03-01 KR KR1020207025799A patent/KR102821949B1/ko active Active
- 2019-03-01 MX MX2020009097A patent/MX2020009097A/es unknown
- 2019-03-01 BR BR112020017739-3A patent/BR112020017739A2/pt unknown
- 2019-03-01 US US16/970,394 patent/US11298345B2/en active Active
- 2019-03-01 PL PL19710107.4T patent/PL3759092T3/pl unknown
- 2019-03-01 JP JP2020544266A patent/JP7225255B2/ja active Active
- 2019-03-01 FI FIEP19710107.4T patent/FI3759092T3/fi active
- 2019-03-01 RU RU2020127537A patent/RU2020127537A/ru unknown
- 2019-03-01 AU AU2019226718A patent/AU2019226718C1/en active Active
- 2019-03-01 CA CA3091783A patent/CA3091783A1/en active Pending
- 2019-03-01 CN CN201980016394.0A patent/CN112004811B/zh active Active
- 2019-03-01 WO PCT/GB2019/050578 patent/WO2019166822A1/en not_active Ceased
- 2019-03-01 ES ES19710107T patent/ES2970784T3/es active Active
-
2022
- 2022-03-04 US US17/687,296 patent/US12383540B2/en active Active
-
2025
- 2025-06-13 US US19/238,079 patent/US20250375432A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023509375A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| MX375424B (es) | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl | |
| JOP20230235A1 (ar) | عقاقير أولية جديدة من الكاتيكولامين للاستخدام في علاج مرض باركنسون | |
| BRPI0820112B8 (pt) | derivados de isoxazol-piridina, seu uso e processos de preparação e medicamento | |
| AR082699A1 (es) | Sales de fenotiazindiaminio, composicion farmaceutica en base al compuesto y proceso de preparacion del compuesto | |
| JP2013512903A5 (enExample) | ||
| SI2743266T1 (en) | Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis | |
| JP2018150302A5 (enExample) | ||
| JP2010523522A5 (enExample) | ||
| JP2016517857A5 (enExample) | ||
| JP2012530779A5 (enExample) | ||
| JP2022533912A5 (enExample) | ||
| JP2013536833A5 (enExample) | ||
| JP2018523665A5 (enExample) | ||
| JP2010513532A (ja) | スフィンゴシン−１−ホスフェート受容体作働薬および拮抗薬化合物 | |
| JP2019524865A5 (enExample) | ||
| ME02452B (me) | Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti | |
| JP2013526544A5 (enExample) | ||
| EA201400183A1 (ru) | Фенил-3-азабицикло[3.1.0]гекс-3-илметаноны и их применение в качестве лекарственного средства | |
| EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
| JP2016537432A5 (enExample) | ||
| JP2022538795A5 (enExample) | ||
| JP2013507371A5 (enExample) |